文献速递甲状腺疾病

K1-70阻断促甲状腺激素受体治疗滤泡性甲状腺癌合并Graves病及眼病

Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy.
PubMed 文献 · Thyroid · 2021-07-08

本文报告1例51岁吸烟女性,患滤泡性甲状腺癌(FTC)合并Graves病(GD)、高滴度TSHR自身抗体及高甲状腺刺激抗体(TSAb)活性和严重Graves眼病(GO)。K1-70按每3周给药、剂量调整至阻断TSAb活性;结果血清TSAb活性下降、GO(突眼与炎症)改善,K1-70单药期间部分转移灶稳定、其余进展减缓。

要点

  • K1-70为TSHR拮抗单克隆抗体,可按TSAb活性调整剂量给药
  • 阻断TSHR刺激后血清TSAb活性下降,GO突眼与炎症改善
  • K1-70单药期间部分转移灶稳定,另一些进展较前减缓

核心结论

  • 阻断TSHR刺激的K1-70可能是GO的有效治疗,并可能使部分FTC合并GD患者获益

主要发现

  • 启动K1-70后血清TSAb活性下降,GO的突眼和炎症改善
  • 在lenvatinib暂停期间接受K1-70单药治疗,数个转移灶稳定,另一些与lenvatinib治疗前相比进展减缓

临床怎么用

  • 对合并GD及严重GO的FTC患者,可考虑以K1-70阻断TSHR刺激并据TSAb活性调整剂量

局限性

  • 为单例病例报告,结论需更多研究验证

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: We report the therapeutic use of K1-70™, a thyrotropin receptor (TSHR) antagonist monoclonal antibody, in a patient with follicular thyroid cancer (FTC), Graves' disease (GD), and Graves' ophthalmopathy (GO). Methods: A 51-year-old female patient, who smoked, presented in October 2014 with FTC complicated by GD, high levels of TSHR autoantibodies with high thyroid stimulating antibody (TSAb) activity, and severe GO. K1-70 was administered at 3 weekly intervals with the dose adjusted to block TSAb activity. Her cancer was managed with lenvatinib and radioiodine therapy. Results: Following initiation of K1-70 therapy, TSAb activity measured in serum decreased and GO (proptosis and inflammation) improved. On K1-70 monotherapy during the pause in lenvatinib, several metastatic lesions stabilized while others showed progression attenuation compared with that before lenvatinib therapy. Conclusions: These observations suggest that blocking TSHR stimulation with K1-70 can be an effective treatment for GO and may also benefit select patients with FTC and GD.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Ryder M, Wentworth M, Algeciras-Schimnich A, et al. Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy. Thyroid. 2021. PMID: 34114495. doi:10.1089/thy.2021.0053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。